DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

More Industry Headlines

Computerized tissue imaging may predict who will benefit from chemotherapy NCI-funded trial to investigate this technology

AI must do these five things to be useful in healthcare Delivering real results can be boils down to just a few capabilities

Solutionreach partners with GE to improve the patient experience Part of the Centricity Partner Program

Radiology practices are willing to pay more for a better RIS Survey finds customizable systems with better workflow justify expense to providers

Functional MR with machine learning may predict patient response to OCD treatment Technique could yield major cost savings

Johnson & Johnson takes aim at robotic surgery market Acquires surgery tech company, Orthotaxy, to develop new orthopedic platforms

New MR imaging technique doesn't require use of contrast agents Detects 98 percent of malignant breast lesions

Ultrasound with 'cheap' blood test improves early-stage liver cancer detection by 40 percent May become standard practice

Working on the next generation of wearables at University of Cincinnati Examining the challenges and potential for wearable biosensors

Siemens, IBM and others join charter to improve cybersecurity Trust outlines ten areas where governments and businesses can reduce threats

Will CMS revise its coverage policy for new PET agents?

by Loren Bonner , DOTmed News Online Editor
The Centers for Medicare and Medicaid Services is in the process of reconsidering its coverage determination for PET radiopharmaceuticals outside of the four it currently reimburses. Stakeholders feel it's important to simplify the process for assessing and approving new PET imaging agents for reimbursement, particularly in light of several new ones coming down the pipeline. Many of these new agents will evaluate myocardial perfusion, as well as the pathophysiology of Alzheimer's disease and Parkinson's disease.

"To go indication by indication on all these new agents we expect to hopefully be approved over the next few years will be a bit cumbersome," said Frederic Fahey, president of the Society of Nuclear Medicine and Molecular Imaging (now SNMMI, formerly SNM).

Story Continues Below Advertisement

Industry Leading Wireless DR Systems from RadmediX

Acuity 14×17 is a completly wireless, cassette sized X-Ray detector. It can easily transform any conventional x-ray room into Digital in just minutes with no special tools required. Get a Quote Today!



SNMMI, in conjunction with the Medical Imaging and Technology Alliance, American College of Radiology, Council on Radionuclides and Radiopharmaceuticals, and World Molecular Imaging Society, are backing this request to remove a second layer of approval outside the FDA's. Discussions have been ongoing for the past year with CMS, and a formal letter was sent to the agency at the end of March.

CMS has a national coverage determination in place denying reimbursement for PET agents outside of its approved list.

"Once you've gone through the rather rigorous FDA process including showing efficacy, you've done a pretty decent job of showing the indications that are being recommended for that agent," said Fahey.

The letter that was submitted to CMS from the five agencies goes on to say that recent advances in imaging and CMS' past experience with PET coverage no longer support a clinical rationale for a national noncoverage policy for new PET agents that have undergone FDA review and approval.

"In my mind, the old way may have been reasonable for FDG. FDG is a pretty non-specific agent. It goes a lot of different places and is used for many different things. But I think as we move forward into molecular imaging, more targeted and hopefully more specific imaging for a particular patient, the indications are probably not going to be as broad and wide," said Fahey.

CMS is accepting public comments until Aug. 10 to determine whether to cover remaining uses of PET.

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED